Biotech Values

[DonShimoda]

Clark here's the pertinent section from the GERN SA transcript:

The ET study was closed to new patients enrollment in December last year when we determined that we have sufficient number of patients to be confident that the hematologic and molecular response data that we had observed and reported at Ash. A total of 20 patients have been enrolled in the trial, which includes 18 patients with ET and 2 patients with polycythemia vera. Patients on the study may continue to receive imetelstat for up to 3 years according to the study protocol. We expect to report periodic updates from the study at future scientific meetings.

Most ET patients are served well with currently available therapies. The purpose of the study in ET was to provide proof of concept for the potential use of imetelstat as a treatment for various other hematologic myeloid malignancies, including myelofibrosis, myelodysplastic syndromes and acute myeloid leukemia. However, the ET data exceeded our expectations, and we are currently working with expert advisers to assess whether there is any potential for the further development of imetelstat in ET.

http://seekingalpha.com/article/1270581-geron-management-discusses-q4-2012-results-earnings-call-transcript?part=single